Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naohiko Inase

Showing results (111-120 of 133) with videos related to

Pageof 14
Sort By:
Respiratory Medicine|September 26, 2021
Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trialYoshikazu Inoue, Takafumi Suda, Hideya Kitamura, et al.
Clinical Lung Cancer|January 24, 2017
EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung CancerRie Sakakibara, Kentaro Inamura, Yuichi Tambo, et al.
Respiratory Investigation|July 29, 2020
A modified GAP model for East-Asian populations with idiopathic pulmonary fibrosisHirotaka Nishikiori, Hirofumi Chiba, Sang Hoon Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2018
High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancerRyo Ariyasu, Shingo Nishikawa, Ken Uchibori, et al.
Japanese Journal of Radiology|February 28, 2020
High-resolution CT features distinguishing usual interstitial pneumonia pattern in chronic hypersensitivity pneumonitis from those with idiopathic pulmonary fibrosisTomoya Tateishi, Takeshi Johkoh, Fumikazu Sakai, et al.
Thoracic Cancer|March 24, 2022
A phase II feasibility study of carboplatin and nab-paclitaxel for advanced non-small cell lung cancer patients with interstitial lung disease (YLOG0114)Hiroyuki Sakashita, Ken Uchibori, Yasuto Jin, et al.
Respiratory Investigation|May 17, 2021
Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in JapanShu Hisata, Masashi Bando, Sakae Homma, et al.
JCO Precision Oncology|February 9, 2022
Deleterious Pulmonary Surfactant System Gene Mutations in Lung Adenocarcinomas Associated With Usual Interstitial PneumoniaTakayuki Honda, Hiroyuki Sakashita, Kyohei Masai, et al.
The American Journal of Surgical Pathology|March 3, 2020
Insulinoma-associated Protein 1 (INSM1) Is a Better Marker for the Diagnosis and Prognosis Estimation of Small Cell Lung Carcinoma Than Neuroendocrine Phenotype Markers Such as Chromogranin A, Synaptophysin, and CD56Rie Sakakibara, Maki Kobayashi, Naoko Takahashi, et al.
Plos One|April 26, 2019
Retrospective evaluation of natural course in mild cases of Mycobacterium avium complex pulmonary diseaseYoshifumi Kimizuka, Yoshihiko Hoshino, Tomoyasu Nishimura, et al.
Pageof 14

Showing results (111-120 of 133) with videos related to

Sort By:
Pageof 14
Respiratory Medicine|September 26, 2021
Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trialYoshikazu Inoue, Takafumi Suda, Hideya Kitamura, et al.
Clinical Lung Cancer|January 24, 2017
EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung CancerRie Sakakibara, Kentaro Inamura, Yuichi Tambo, et al.
Respiratory Investigation|July 29, 2020
A modified GAP model for East-Asian populations with idiopathic pulmonary fibrosisHirotaka Nishikiori, Hirofumi Chiba, Sang Hoon Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|March 3, 2018
High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancerRyo Ariyasu, Shingo Nishikawa, Ken Uchibori, et al.
Japanese Journal of Radiology|February 28, 2020
High-resolution CT features distinguishing usual interstitial pneumonia pattern in chronic hypersensitivity pneumonitis from those with idiopathic pulmonary fibrosisTomoya Tateishi, Takeshi Johkoh, Fumikazu Sakai, et al.
Thoracic Cancer|March 24, 2022
A phase II feasibility study of carboplatin and nab-paclitaxel for advanced non-small cell lung cancer patients with interstitial lung disease (YLOG0114)Hiroyuki Sakashita, Ken Uchibori, Yasuto Jin, et al.
Respiratory Investigation|May 17, 2021
Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in JapanShu Hisata, Masashi Bando, Sakae Homma, et al.
JCO Precision Oncology|February 9, 2022
Deleterious Pulmonary Surfactant System Gene Mutations in Lung Adenocarcinomas Associated With Usual Interstitial PneumoniaTakayuki Honda, Hiroyuki Sakashita, Kyohei Masai, et al.
The American Journal of Surgical Pathology|March 3, 2020
Insulinoma-associated Protein 1 (INSM1) Is a Better Marker for the Diagnosis and Prognosis Estimation of Small Cell Lung Carcinoma Than Neuroendocrine Phenotype Markers Such as Chromogranin A, Synaptophysin, and CD56Rie Sakakibara, Maki Kobayashi, Naoko Takahashi, et al.
Plos One|April 26, 2019
Retrospective evaluation of natural course in mild cases of Mycobacterium avium complex pulmonary diseaseYoshifumi Kimizuka, Yoshihiko Hoshino, Tomoyasu Nishimura, et al.
Pageof 14